Clear cell renal cell carcinoma Trials in Nashville, United States
Conditions / Clear cell renal cell carcinoma / Nashville, United States
Clear cell renal cell carcinoma has been the subject of sustained clinical investigation across multiple research sites.
21 total trials for this combination
Showing top 10 of 21 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03284385 | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | ACTIVE_NOT_RECRUITING | — |
| NCT00378703 | Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer | COMPLETED | PHASE2 |
| NCT04374877 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT06661720 | Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | RECRUITING | PHASE3 |
| NCT00335556 | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | COMPLETED | PHASE2 |
| NCT02293980 | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT03284385 | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | ACTIVE_NOT_RECRUITING | — |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | TERMINATED | PHASE1 |
| NCT00326898 | Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery | COMPLETED | PHASE3 |